The importance of immunology in tumor response to radiotherapy represents a major opportunity for our discipline. Novel therapies have emerged which target the immune cells. Combinations of such therapies to radiotherapy might translate into better local tumor control rates and also into better distant control given the possibility to use radiotherapy as an immunological enhancer of the anti-tumor immune response. Drugs targeting the immune checkpoints such and PD-1, PD-L1 and CTLA-4 blockers are among the first agent; moreover, several other agents are also in development. Thus, the selection of the optimal combination based on a sound rationale and proper patient selection will be key.
Speakers from major European and North American institutions and from leading groups involved in the field will present their data in order to discuss clinical transfer opportunities. This meeting will be a unique opportunity to cover major fields including immunological biomarkers for patient selection, clinical trial design and proposals for innovative trial designs. Numerous prospects for brainstorming, learning and networking will also be available.
Gustave Roussy - Villejuif - France